efalizumab


Also found in: Wikipedia.

efalizumab

A recombinant, humanized monoclonal antibody to CD11 a used to treat moderate to severe PSORIASIS.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
Mentioned in ?
References in periodicals archive ?
* Autoimmune haemolytic anemia: Occurs 4-6 months after the start of treatment with efalizumab.
Biologies in dermatology: a brief review
* Efalizumab (Raptiva), injected by patients once a week
Learn the connection between psoriasis and heart disease: research shows that this common skin condition can increase your risk of cardiovascular problems
Good to excellent responses were achieved with ustekinumab at doses of either 45 mg or 90 mg, depending on body weight, in 9 of 11 psoriasis patients who had experienced treatment failures on multiple biologics, including infliximab (11 patients), etanercept (10), efalizumab (9), adalimumab (7), and golimumab (3) (Int.
Switching biologics for psoriasis 'okay'
Efalizumab, lokosit fonksiyon-iliskili antijen-1 (LFA-1)'in alt-parcasi olan CD11a'ya karsin gelistirilmis insanlastirilmis monoklonal antikordur.
New treatment alternatives in the management of non-infectious intraocular inflammations: biologic agents/Enfeksiyoz olmayan intraokuler inflamasyonlarin kontrolunde yeni secenekler: biyolojik ajanlar
However, risk is a concern because of what happened with the biologic efalizumab (Raptiva), which was taken off the market after three cases (two fatal) of progressive multifocal leukoencephalopathy, a brain infection, were reported in patients treated with the drug for psoriasis.
Ustekinumab approved for psoriasis
The Food and Drug Administration has advised prescribers not to initiate Raptiva (efalizumab) treatment for new patients and to engage in discussions with those already on the therapy of avenues for transitioning to alternative treatments.
Genentech to remove Raptiva from market
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliksimab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
Anti-TNF agents in Behcet's disease treatment/Behcet hastaligi tedavisinde anti-TNF ajanlar
Ng, "The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab," Journal of Pharmaceutical Sciences, vol.
Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis
After an effective monoclonal antibody therapy (infliximab, etanercept, and efalizumab), an increase of CD[4.sup.+]CD[25.sup.+]FOXP[3.sup.+] cells in the blood of psoriatic patients is observed as well as in the previously affected skin after treatment with adalimumab (17, 24, 43).
The role of regulatory T cells and anti-inflammatory cytokines in psoriasis
Efalizumab, a monoclonal antibody and a T-cell modulator, has also shown a good response in patients with DLE.
Oral Discoid Lupus Erythematosus: A Case Effectively Managed and Differentiated with other Overlapping Diseases

Medical browser ?
Full browser ?